Heparin-binding defective lipoprotein lipase is unstable and causes abnormalities in lipid delivery to tissues

Journal of Clinical Investigation

Volumn 107, Issue 9, 2001, Pages 1183-1192

  Lutz, E Peer ^a   Merkel, Martin ^b,c   Kako, Yuko ^a   Melford, Kristan ^d   Radner, Herbert ^e   Breslow, Jan L ^c   Bensadoun, André ^d   Goldberg, Ira J ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF HAMBURG   (Germany)

^c ROCKEFELLER UNIVERSITY   (United States)

^d Department of Obstetrics Gynecology   (United States)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; LIPOPROTEIN LIPASE; PROTEOHEPARAN SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CAPILLARY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME STABILITY; GENE EXPRESSION; GENE MUTATION; KIDNEY; KNOCKOUT MOUSE; LIPID STORAGE; LIPID TRANSPORT; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

EID: 0035014452     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11774     Document Type: Article

References (42)

1. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis
2. Effects of heparin on lipoprotein lipase from bovine milk
3. Involvement of cell surface heparin sulfate in the binding of lipoprotein lipase to cultured bovine endothelial cells
4. Identification and characterization of the endothelial cell surface lipoprotein lipase receptor
5. Oligosaccharride sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase
6. Interaction of lipoprotein lipase with heparin fragments and with heparan sulfate: Stoichiometry, stabilization, and kinetics
7. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor
8. Molecular modeling of protein-glycosaminoglycan interactions
9. Comparative analysis of structurally defined heparin binding sequences reveals a distinct spatial distribution of basic residues
10. Analysis of putative heparin-binding domains of fibroblast growth factor-1. Using site-directed mutagenesis and peptide analogues
11. Hepatic and extrahepatic uptake of intravenously injected lipoprotein lipase
12. Mutagenesis in four candidate heparin binding regions (residues 279-282, 291-304, 390-393, and 439-448) and identification of residues affecting heparin binding of human lipoptotein lipase
13. Binding of lipoprotein lipase to heparin. Identification of five critical residues in two distinct segments of the amino-terminal domain
14. Site-directed mutagenesis of a putative heparin binding domain of avian lipoprotein lipase
15. Chimeras of hepatic lipase and lipoprotein lipase. Domain localization of enzyme-specific properties
16. Subdomain chimeras of hepatic lipase and lipoprotein lipase. Localization of heparin and cofactor binding
17. Identification of a heparin-binding domain in the distal carboxyl-terminal region of lipoprotein lipase by site-directed mutagenesis
18. Contribution of the carboxy-terminal domain of lipoprotein lipase to interaction with heparin and lipoproteins
19. Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice
20. The heparin-binding proteins apolipoprotein E and lipoprotein lipase enhance cellular proteoglycan production
21. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3
22. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes
23. Induced mutant mice expressing lipoprotein lipase exclusively in muscle have subnormal triglycerides yet reduced high density lipoprotein cholesterol levels in plasma
24. Human lipoprotein lipase: Relationship of activity, heparin affinity, and conformation as studied with monoclonal antibodies
25. Lipoprotein lipase activity and mRNA levels in bovine tissues
26. Production and use of an inhibitory monoclonal antibody to human lipoprotein lipase
27. Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice. Effects on lipoproteins and atherosclerosis
28. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum
29. Transforming growth factor beta (TGF-beta) inhibits hepatocyte DNA synthesis independently of EGF binding and EGF receptor autophosphorylation
30. Intracellular localization and metabolism of chylomicron remnants in the livers o flow density lipoprotein receptor-deficient mice and apoE-deficient mice. Evidence for slow metabolism via an alternative apoE-dependent pathway
31. Lipoprotein lipase expression level influences tissue clearance of chylomicron retinyl ester
32. Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: Direct evidence that lipoprotein lipase bridging occurs in vivo
33. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice
34. Association of plasma lipoproteins with postheparin lipase activities
35. Segments in the C-terminal folding domain of lipoprotein lipase important for binding to the low density lipoprotein receptor-related protein and to heparan sulfate proteoglycans
36. Forms of lipoprotein lipase in rat tissues: In adipose tissue the proportion of inactive lipase increases on fasting
37. The response of lipoprotein lipase to feeding and fasting. Evidence for posttranslational regulation
38. Regulation of lipoprotein lipase in the diabetic rat
39. Anti-heparin immunoglobulins, a factor of thrombosis, hyperlipemia and atherosclerosis
40. Acquired type I hyperlipoproteinemia with systemic lupus erythematosus, dysglobulinemia and heparin resistance
41. Plasma delivery of retinoic acid to tissues in the rat